<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240916063059N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-10-17</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the topical effectiveness of Black fat-tail scorpion oil on pain in patients with chronic sciatica</public_title>
      <acronym>-</acronym>
      <scientific_title>Investigating the effectiveness of topical use of Black fat-tailed scorpion oil (Androctonus crassicauda ) on the pain of patient with chronic sciatica: A double-blind randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-11-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79104</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Due to compliance with ethical principles and not depriving patients of common treatments, study participants (both groups) can take diclofenac 25 mg tablets up to 2 times a day, one at a time, if they feel the need and have severe pain. As much as medicinal ointment is more effective than placebo on the pain intensity of patients, the amount of oral pain reliever (diclofenac) should be lower in the first group than in the second group (placebo ointment recipient). Accordingly, the participants are asked to write down the number of diclofenac consumed per day and finally inform the presenter, Randomization description: Random block method is used to divide people into two groups. The first group uses oleogel containing scorpion oil and placebo (oleogel without scorpion oil) is used on the second group. Simple Random Sampling (Simple Random Sampling) is one of the statistical sampling methods in which people in the community have an equal chance of being selected. In this method, each element of the desired statistical population has an equal chance to be selected. In this method, the needed people or objects are randomly selected from the list of the statistical population that is numbered and prepared for this purpose. According to the law of probability, the selected people should have the same characteristics as the society from which they were selected. The advantage of the authentication block method is the balance of the number of participants in two groups, Blinding description: Medicines and placebo are in similar tubes with the same shape, color and smell. The specific codes are written by the pharmacist on the label of the medicine container and the placebo so that the patients and the researcher do not know the meaning of the codes.</study_design>
      <phase>3</phase>
      <hc_freetext>Chronic Sciatica.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Recipient of topical ointment containing scorpion oil: 3 times a day (morning, noon, night) each time in the size of 2 knuckles in the lumbar area (from L1 down), buttock area to the middle of the back of the thigh on the side that hurts, for 4 The week will be rubbed along with the massage. If they feel the need and have severe pain, they can take diclofenac 25 mg tablets up to 2 times a day, one at a time. Intervention 2: Control group: recipient of topical ointment containing liquid paraffin: 3 times a day (morning, noon, night) each time the size of 2 knuckles in the lumbar region (from L1 down), buttock region to the middle of the back of the thigh on the side that has pain. It will be applied for 4 weeks along with massage. If they feel the need and have severe pain, they can take diclofenac 25 mg tablets up to 2 times a day, one at a time.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Yazdan Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Pharmacy, Alborz University of Medical Sciences.,Valiasr Blvd.,Shura Blvd.,Azimieh.,Karaj</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149779453</zip>
        <telephone>+98 26 3419 7000</telephone>
        <email>yazdanamini1213@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Yazdan Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Pharmacy, Alborz University of Medical Sciences., Valie-asr Blvd., Shura Blvd., Azimieh., Karaj</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149779453</zip>
        <telephone>+98 26 3419 7000</telephone>
        <email>yazdanamini1213@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1- Patient with chronic sciatica pain for at least 12 weeks
2- Age above 18 years
3- Pain equivalent to 4 or more based on VAS criteria
4- Willingness of patients to cooperate in the study
5- People without communication problems.
6- Pain that is not due to malignancies, inflammatory joint diseases, etc.
7- Don't have congenital abnormalities of the spine and bone fractures.
8- Not a candidate for surgery.
9- Absence of any history of surgery in the back area
10- Not having a history of alcohol and narcotic drugs
11- BMI between 18.4 and 35</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1- Pregnancy or breastfeeding
2- causing severe side effects
3- Severe sensitivity to any of the drugs used in the study
4- Lack of consent to continue participating in the study
5- Patients with a history of lumbar disc surgery
6- Concurrent acute illness or accident during the study
7- People suffering from favism
8- Intensification of the patient's pain and its lack of control
9- Use of non-pharmacological soothing treatments
10- Use of painkillers outside the study program during the study
11- Symptoms of cauda equina syndrome
12- Occurrence of serious clinical symptoms during treatment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M00-M99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disease of the musculoskeletal system and connective tissue</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Recipient of topical ointment containing scorpion oil: 3 times a day (morning, noon, night) each time in the size of 2 knuckles in the lumbar area (from L1 down), buttock area to the middle of the back of the thigh on the side that hurts, for 4 The week will be rubbed along with the massage. If they feel the need and have severe pain, they can take diclofenac 25 mg tablets up to 2 times a day, one at a time.</i_keyword>
      <i_keyword>Control group: recipient of topical ointment containing liquid paraffin: 3 times a day (morning, noon, night) each time the size of 2 knuckles in the lumbar region (from L1 down), buttock region to the middle of the back of the thigh on the side that has pain. It will be applied for 4 weeks along with massage. If they feel the need and have severe pain, they can take diclofenac 25 mg tablets up to 2 times a day, one at a time.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of leg and back pain. Timepoint: at the beginning of the study (before the start of the intervention) and 7, 14, 21 and 28 days after the start of the study. Method of measurement: Visual Analogue Scale for leg and back pain intensity.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The number of diclofenac tablets taken daily. Timepoint: Length of study. Method of measurement: number.</sec_outcome>
      <sec_outcome>The degree of disability of patients. Timepoint: before the start of the study and 4 weeks after the start of the study (end of the study). Method of measurement: Questionnaire Oswestry Disability Index.</sec_outcome>
      <sec_outcome>Skin Adverse effect. Timepoint: Days 3, 7, 14, 21 and 28 after the start of the study. Method of measurement: Skin side effects form based on CTCAE version 5 (Common Terminology Criteria for Adverse effects).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-09-18</approval_date>
        <contact_name>Research Ethics Committees of Alborz University of Medical Sciences</contact_name>
        <contact_address>Deputy Research Building., Shahid Safarian Alley., 45-meter Golshahr St., Karaj Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
